Wide Ranks

GSK

GSK plc

34.33

Top Statistics
Market Cap 70 B Forward PE 8.02 Revenue Growth -1.70 %
Current Ratio 0.81 Trailing PE 22.44 Earnings Growth 0.00 %
Profit Margins 8.02 % Peg Ratio Dividend Yield 4.56 %
Enterprice / EBITA 16.46 Enterprise / Revenue 4.87 Price To Sales Trailing12 Months 2.24
Profitability
Profit Margins 8.02 % Operating Margins 8.33 %
Balance Sheet
Total Cash 3 B Total Cash Per Share 0.7870 Total Debt 16 B
Total Debt To Equity 119.37 Current Ratio 0.81 Book Value Per Share 3.43
All Measures
Short Ratio 332.00 % Message Board Id finmb_275442 Shares Short Prior Month 16 M
Return On Equity 0.2185 City Brentford Uuid a7130272-5c50-3936-b6ce-1eb2c57020e3
Previous Close 34.02 First Trade Date Epoch Utc 323 M Book Value 3.43
Beta 0.3300 Total Debt 16 B Volume 2 M
Price To Book 10.00 Last Split Date 1 B Fifty Two Week Low 32.83
Total Cash Per Share 0.7870 Total Revenue 31 B Shares Short Previous Month Date 1 B
Target Median Price 45.00 Max Age 86400 Recommendation Mean 2.43
Sand P52 Week Change 0.3133 Operating Margins 8.33 % Last Dividend Value 0.3890
Target Mean Price 45.95 Net Income To Common 2 B Ask 34.47
Short Percent Of Float 0.0115 Implied Shares Outstanding 2 B Last Fiscal Year End 1 B
Trailing Peg Ratio 77.42 % Average Daily Volume10 Day 6 M Average Volume10days 6 M
Total Cash 3 B Next Fiscal Year End 1 B Revenue Per Share 15.38
Held Percent Insiders 0.0006 Ebitda Margins 29.57 % Dividend Rate 1.56
Trailing PE 22.44 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 34.02 Target Low Price 37.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 37.57 Open 34.19 Dividend Yield 4.56 %
Free Cashflow 6 B Return On Assets 0.0724 Time Zone Short Name EST
Trailing Eps 1.53 Day Low 34.19 Address1 980 Great West Road
Trailing Annual Dividend Rate 0.6100 Price Hint 2 Shares Outstanding 2 B
Target High Price 58.00 Website https://www.gsk.com 52 Week Change -0.0461
Average Volume 5 M Forward Eps 4.30 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 51.60 % Last Split Factor 1226:1000
Regular Market Day High 34.47 Is_sp_500 False Profit Margins 8.02 %
Debt To Equity 119.37 Fifty Two Week High 45.93 Day High 34.47
Shares Short 23 M Regular Market Open 34.19 Industry Key drug-manufacturers-general
Bid 34.27 Earnings Growth 0.00 % Enterprise To Revenue 4.87
Revenue Growth -1.70 % Shares Percent Shares Out 0.0115 Operating Cashflow 7 B
Five Year Avg Dividend Yield 483.00 % Currency USD Market Cap 70 B
Time Zone Full Name America/New_York Is_nasdaq_100 False Zip TW8 9GS
Payout Ratio 98.54 % Quote Type EQUITY Industry Drug Manufacturers - General
Ex Dividend Date 1 B Regular Market Day Low 34.19 Held Percent Institutions 0.1537
Long Name GSK plc Current Price 34.33 Address2 Middlesex
Enterprise To Ebitda 16.46 Trailing Annual Dividend Yield 1.79 % Financial Currency GBP
Current Ratio 0.81 Gross Margins 72.39 % Industry Disp Drug Manufacturers - General
Number Of Analyst Opinions 7 Country United Kingdom Float Shares 3 B
Two Hundred Day Average 40.68 Ir Website http://www.gsk.com/investors.html Enterprise Value 152 B
Price To Sales Trailing12 Months 2.24 Forward PE 8.02 Regular Market Volume 2 M
Last Dividend Date 1 B Ebitda 9 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

It operates through two segments, Commercial Operations and Total R&D.

The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.

It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic  alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.

The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.

GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

dom.